|
Atorvastatin lowers plasma LDL cholesterol and CRP in type 2 diabetics
(Science Letter Via Thomson Dialog NewsEdge)
Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients.
According to a study from Japan, "We investigated the meaning and the worth of lowering low-density lipoprotein cholesterol (LDL-C) to less than 100 mg/dL in Japanese type 2 diabetic patients using atorvastatin. As a multicenter open-labeled study, 84 type 2 diabetic Japanese patients with hypercholesterolemia were enrolled between September 2003 and April 2004."
S. Yamada and colleagues at the Kitasato Institute Hospital explained, "Subjects received 16 weeks of treatment with atorvastatin. High-sensitive C-reactive protein (hs-CRP), plasminogen activator inhibitor 1, monocyte chemotactic protein 1, interleukin 6, urine albumin-creatinine ratio, hemoglobin A1c, total cholesterol, and LDL-C were measured at baseline and after 8 and 16 weeks of treatment. According to the Adult Treatment Panel III of the National Cholesterol Education Program, we divided the subjects into responders (final LDL-C <100 mg/dL) and nonresponders (final LDL-C greater than or equal to100 mg/dL)."
The data showed, "After 16 weeks of atorvastatin treatment, as well as a reduction of total cholesterol and LDL-C, a significant reduction of hs-CRP was observed. Plasminogen activator inhibitor 1, monocyte chemotactic protein 1, and interleukin 6 were not changed. After stratification, hs-CRP declined only in responders."
"We concluded," stated the authors, "that atorvastatin not only improved hypercholesterolemia, but also reduced CRP even in Japanese diabetic patients. The results of this stratified study suggest that achievement of the Adult: Treatment Panel III treatment goal of LDL-C might assure a reduction of inflammation, which is associated with cardiovascular events."
Yamada and colleagues published their study in Metabolism - Clinical and Experimental (Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients. Metabolism, 2006;55(1):67-71).
For more information, contact S. Yamada, Kitasato Institute Hospital, Dept. Internal Medicine, Minato Ku, 5-9-1 Shirokane, Tokyo 1088642, Japan.
Publisher contact information for the journal Metabolism - Clinical and Experimental is: W B Saunders Co-Elsevier Inc., Independence Square West Curtis Center, Ste. 300, Philadelphia, PA 19106-3399, USA.
Keywords: Tokyo, Japan, Angiology, Atorvastatin, Cardiology, Cardiovascular, Diabetes, Endocrinology, Hematology, Hypercholesterolemia, Lipoprotein, Metabolism.
This article was prepared by Science Letter editors from staff and other reports. Copyright 2006, Science Letter via NewsRx.com.
[ Back To TMCnet.com's Homepage ]
|
INDUSTRIES
Activate Email 
INDUSTRIES
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO West, September 1-3, 2009. Los Angeles, CA.
